Botanix Pharmaceuticals has been granted a patent for a treatment regime using a topical liquid or gel composition containing cannabidiol for dermatitis and inflammatory skin conditions. The regime involves administering between 50 mg and 3000 mg of the composition daily. GlobalData’s report on Botanix Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Botanix Pharmaceuticals Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Botanix Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Botanix Pharmaceuticals's grant share as of April 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11896560B2) discloses a treatment regime for dermatitis and inflammatory skin conditions involving the administration of a topical liquid or gel composition containing cannabidiol, hexamethyldisiloxane, octamethyltrisiloxane, and a residual solvent. The regime specifies a dosage range of 50 mg to 3000 mg of the composition, with cannabidiol concentration between 1% to 15% w/w. The residual solvent, comprising fatty acids, alcohols, glycols, or alkanes, is selected to ensure minimal evaporation at skin temperature over 24 hours, with a total daily dose of cannabidiol ranging from 20 mg to 2000 mg.

Furthermore, the patent outlines the frequency of administration, suggesting application to the skin between 1 and 5 times per day, delivering 20 mg to 400 mg of cannabidiol per administration. Specific formulations, such as 4% w/w cannabidiol and 1-10% wt/wt C2-C6 alcohol, are detailed within the claims. The regime also emphasizes the use of hexamethyldisiloxane in the composition and lists various residual solvent options like alkyl polypropylene glycol and isostearyl alcohol. Additionally, the patent highlights the application of the treatment regime for dermatitis and atopic dermatitis, offering a comprehensive approach to addressing these skin conditions.

To know more about GlobalData’s detailed insights on Botanix Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies